Patents matching “anti-”

US 10137104

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

US 10123974

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

US 10118938

Arsenoplatin anti-cancer agents

Northwestern University · Granted Nov 6, 2018 · Expires Nov 1, 2038

US 10117882

Anti-inflammatory properties of marine lipid compositions

AKER BIOMARINE ANTARCTIC AS · Granted Nov 6, 2018 · Expires Nov 1, 2038

US 10106620

Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10100012

Compounds as anti-tubercular agents

DRUG DISCOVERY RESEARCH CENTRE · Granted Oct 16, 2018 · Expires Oct 11, 2038

US 10093745

Anti-CSPG4 fusions with interferon for the treatment of malignancy

The Regents of the University of California · Granted Oct 9, 2018 · Expires Oct 4, 2038

US 10087230

Murine anti-NY-ESO-1 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 2, 2018 · Expires Sep 27, 2038

US 10080739

Aryl imidazoles and their use as anti-cancer agents

APTOSE BIOSCIENCES INC. · Granted Sep 25, 2018 · Expires Sep 20, 2038

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

US 10072051

Anti-inflammatory lipopeptide and preparing method and application thereof

EAST CHINA NORMAL UNIVERSITY · Granted Sep 11, 2018 · Expires Sep 6, 2038

US 10072070

Potent anti-influenza A neuraminidase subtype N1 antibody

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 11, 2018 · Expires Sep 6, 2038

US 10059762

Anti-EGFR activatable antibodies

CytomX Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

US 10047160

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Aug 14, 2018 · Expires Aug 9, 2038

US 10040858

Anti-CSF1R antibodies for treating PVNS

Five Prime Therapeutics, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

US 10028911

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Pacira Pharmaceuticals, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

US 10023654

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

US 10023641

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

US 10023916

Markers of tumor cell response to anti-cancer therapy

REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

US 10023642

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

US 10017580

Humanized anti-Tn-MUC1 antibodies and their conjugates

ADC THERAPEUTICS SA · Granted Jul 10, 2018 · Expires Jul 5, 2038

US 10010587

IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Nektar Therapeutics · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 10000564

Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jun 19, 2018 · Expires Jun 14, 2038

US 9974744

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted May 22, 2018 · Expires May 17, 2038